Marc I. Broudy

Discovery of 3-[2-(Imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Wei‐Sheng Huang, Chester A. Metcalf, Raji Sundaramoorthi et al. · Journal of Medicinal Chemistry · 2010 · 357 citations · Full text

Drug Target, Immunology, Molecular Biology +25

HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE

David M. Stresser, Marc I. Broudy, Thuy Ho et al. · Drug Metabolism and Disposition · 2004 · 128 citations

9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation

Wei‐Sheng Huang, Xiaotian Zhu, Yihan Wang et al. · Journal of Medicinal Chemistry · 2009 · 46 citations · Full text

Immunology, Pharmacotherapy, Active Enzyme Conformation +19

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

Victor M. Rivera, Qihong Xu, Frank Wang et al. · Blood · 2007 · 21 citations

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

Mathew Thomas, Wei‐Sheng Huang, David Wen et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 18 citations · Full text

Hetero-monocyclic Derivatives, Molecular Pharmacology, Medicinal Chemistry +9